LATS1: A Protein Potential Drug Target for Cancer and Other Diseases

Target Name: LATS1

NCBI ID: G9113

LATS1

LATS1: A Protein Potential Drug Target for Cancer and Other Diseases

LATS1 (Large tumor suppressor kinase 1, transcript variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a non-catalytic protein that is characterized by its ability to suppress the activity of several transcription factors, including TGF-β1, p53, and NF-kappa-B. LATS1 has been implicated in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

Recent studies have identified LATS1 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of LATS1 as a drug target is due to its ability to inhibit the activity of transcription factors that are involved in the development and progression of these diseases.

One of the mechanisms by which LATS1 can be used as a drug target is its ability to inhibit the activity of TGF-β1, a transcription factor that is involved in the development and maintenance of cancer. TGF-β1 has been shown to promote the formation of cancer cells, and LATS1 has been shown to inhibit its activity. This means that LATS1 could be used as a TGF-β1 inhibitor, which could potentially lead to the suppression of cancer cell growth and the development of new treatments for cancer.

Another potential mechanism by which LATS1 could be used as a drug target is its ability to inhibit the activity of p53, a transcription factor that is involved in the regulation of apoptosis, or cell death. p53 has been shown to play a crucial role in the regulation of cell death, and LATS1 has been shown to inhibit its activity. This means that LATS1 could be used as a p53 inhibitor, which could potentially lead to the inhibition of cell death, including cancer cell growth.

In addition to its potential ability to inhibit TGF-β1 and p53, LATS1 has also been shown to interact with several other transcription factors, including NF-kappa-B. NF-kappa-B is a transcription factor that is involved in the regulation of inflammation and cellular processes such as inflammation, pain, and fever. LATS1 has been shown to interact with NF-kappa-B and may be involved in the regulation of these processes.

Given its potential as a drug target, LATS1 has been the focus of intense research in recent years. Researchers have been studying the molecular mechanisms by which LATS1 functions, as well as the potential therapeutic benefits of LATS1 inhibition. One of the challenges in studying LATS1 is its complex biochemical and cellular interactions, as well as its diverse expression patterns across different tissues and organs.

In addition to its potential as a drug target, LATS1 has also been identified as a potential biomarker for several diseases, including cancer. The expression of LATS1 has been shown to be associated with the development and progression of cancer, and LATS1 has been shown to be a potential therapeutic target for cancer. Researchers have been studying the potential clinical applications of LATS1 inhibitors, including their potential use as a cancer treatment.

Overall, LATS1 is a protein that has significant potential as a drug target and biomarker. Its ability to inhibit the activity of TGF-β1, p53, and NF-kappa-B makes it a promising target for the treatment of various diseases, including cancer. Further research is needed to fully understand the molecular mechanisms by which LATS1 functions and its potential clinical applications.

Protein Name: Large Tumor Suppressor Kinase 1

Functions: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Plays a role in mammary gland epithelial cell differentiation, both through the Hippo signaling pathway and the intracellular estrogen receptor signaling pathway by promoting the degradation of ESR1 (PubMed:28068668)

The "LATS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LATS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets